DoubleChecks

What was claimed

Ivermectin (72mg/day) and Fenbendazole (1500mg/day) combined with oncology drugs caused complete remission of stage IV breast cancer (with liver and gallbladder mets) in just 3 months after conventional treatments failed

Our verdict

Inaccurate

There is no high‑quality evidence (randomized trials or replicated controlled studies) showing this combination reliably produces rapid complete remissions; available evidence is limited to isolated case reports and observational/real‑world claims that cannot establish reliability. Oncology experts and professional societies state there is currently no evidence in humans that ivermectin is effective at decreasing cancer growth or improving outcomes, beyond very early preclinical studies in cells and animals. A phase 1/2 study in metastatic triple‑negative breast cancer showed no clear added benefit of ivermectin when combined with immunotherapy. (Only 2 of 3 AI systems responded.)

1 of 2 AI systems agree8 sources citedChecked Jul 4, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

The combination reliably achieves complete remission of stage IV breast cancer within three months after conventional treatment failure

Incorrect90%
1 AI checked

Ivermectin is an effective cancer treatment that can induce remission when combined with oncology drugs

Incorrect95%
1 AI checked

Fenbendazole is an effective cancer treatment that can induce remission when combined with oncology drugs

Incorrect95%
1 AI checked

There is solid clinical evidence that high‑dose ivermectin (around 72 mg/day) is safe and effective for metastatic breast cancer

Incorrect95%
1 AI checked

There is solid clinical evidence that very high‑dose fenbendazole (around 1500 mg/day) is safe and effective for stage IV breast cancer with liver and gallbladder metastases

Incorrect95%
1 AI checked

Using ivermectin and fenbendazole for cancer is evidence‑based and not considered misinformation by oncology experts

Incorrect95%
1 AI checked

Mainstream oncology bodies endorse or support using ivermectin and fenbendazole as cancer treatments or adjuncts

Incorrect98%
1 AI checked

Fenbendazole was given at 1500 mg per day in this context

Misleading80%
1 AI checked

Ivermectin was given at 72 mg per day in this context

Misleading85%
1 AI checked

Ivermectin (72 mg/day) and Fenbendazole (1500 mg/day) combined with oncology drugs caused complete remission of stage IV breast cancer (with liver and gallbladder mets) in just 3 months after conventional treatments failed

Can’t verify68%
2 of 3 AIs agree·Perplexity: Incorrect

Verified against 8 sources

pmc.ncbi.nlm.nih.govfrontiersin.orgclinicaltrials.govyoutube.comavera.orgcancer.orgoncologynewscentral.comconnection.asco.org

Detailed Analysis

There is no high‑quality clinical evidence that ivermectin and fenbendazole at the stated doses cause rapid complete remission of stage IV breast cancer in humans. Major oncology bodies explicitly advise against using these drugs for cancer treatment, and the specific claimed regimen and outcome are unsupported and potentially dangerous. The response misrepresents very limited case reports and preclinical data as proven curative therapy.

Why this verdict

  • There is no high‑quality clinical evidence that ivermectin and fenbendazole at the stated doses cause rapid complete remission of stage IV breast cancer in humans.
  • Major oncology bodies explicitly advise against using these drugs for cancer treatment, and the specific claimed regimen and outcome are unsupported and potentially dangerous.
  • The response misrepresents very limited case reports and preclinical data as proven curative therapy.

Claims checked

The reported complete remission in 3 months is proven to be caused by ivermectin and fenbendazole rather than other oncology drugs or factors

Incorrect90%
In analogous fenbendazole case reports and other anecdotal stories, patients were receiving standard cancer therapies simultaneously, and experts stress that it is impossible to know whether outcomes were due to fenbendazole or other treatments.[1] [6] Attributing remission solely to antiparasitic drugs without controlled data is not supported by current evidence.[6] [5]

This claim may mislead readers without added context.

Ivermectin is an effective cancer treatment that can induce remission when combined with oncology drugs

Incorrect95%
Oncology experts and professional societies state there is currently no evidence in humans that ivermectin is effective at decreasing cancer growth or improving outcomes, beyond very early preclinical studies in cells and animals.[7] [5] A phase 1/2 study in metastatic triple‑negative breast cancer showed no clear added benefit of ivermectin when combined with immunotherapy.[7] [3]

This claim may mislead readers without added context.

Fenbendazole is an effective cancer treatment that can induce remission when combined with oncology drugs

Incorrect95%
The American Cancer Society and oncology clinicians state fenbendazole has not been tested or proven as a safe or effective cancer treatment in humans.[6] [5] A small case series reports patients self‑administering fenbendazole alongside other therapies, but the authors emphasize that evidence is very limited and remission cannot be attributed to fenbendazole alone.[1] [6]

This claim may mislead readers without added context.

What other AI think

ClaudeDid not respond
The statement is based on anecdotal and very limited case reports, not on controlled evidence. Dosing claims in the statement do not match typical reported human use and raise safety concerns.

Why this verdict

  • The statement is based on anecdotal and very limited case reports, not on controlled evidence.
  • Dosing claims in the statement do not match typical reported human use and raise safety concerns.

Claims checked

The combination reliably achieves complete remission of stage IV breast cancer within three months after conventional treatment failure

Incorrect90%
There is no high‑quality evidence (randomized trials or replicated controlled studies) showing this combination reliably produces rapid complete remissions; available evidence is limited to isolated case reports and observational/real‑world claims that cannot establish reliability.

This claim may mislead readers without added context.

Fenbendazole was given at 1500 mg per day in this context

Misleading80%
Published human case reports of fenbendazole use describe much lower reported daily ranges (for example ~222–444 mg/day in a recent case series), so 1500 mg/day is not representative of the documented anecdotal doses and lacks safety/efficacy validation.

This claim may mislead readers without added context.

Ivermectin was given at 72 mg per day in this context

Misleading85%
Typical human ivermectin dosing is much lower (single doses around 0.2 mg/kg), so 72 mg/day is substantially higher than standard regimens and would raise toxicity concerns; high daily dosing at that level is not a validated cancer regimen.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks